Aliases & Classifications for Dry Eye Syndrome

MalaCards integrated aliases for Dry Eye Syndrome:

Name: Dry Eye Syndrome 12 14
Dry Eye Syndromes 52 42 69
Tear Film Insufficiency 12
Xerophthalmia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:10140
ICD10 33 H04.12
MeSH 42 D015352
NCIt 47 C34553
UMLS 69 C0013238

Summaries for Dry Eye Syndrome

MalaCards based summary : Dry Eye Syndrome, also known as dry eye syndromes, is related to keratoconjunctivitis sicca and smarca4-deficient sarcoma of thorax, and has symptoms including dryness of eye and dacryops. An important gene associated with Dry Eye Syndrome is AQP5 (Aquaporin 5), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Miconazole and Povidone have been mentioned in the context of this disorder. Affiliated tissues include eye, salivary gland and thyroid, and related phenotype is vision/eye.

Wikipedia : 72 Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is the condition of having dry... more...

Related Diseases for Dry Eye Syndrome

Diseases related to Dry Eye Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 70)
id Related Disease Score Top Affiliating Genes
1 keratoconjunctivitis sicca 11.7
2 smarca4-deficient sarcoma of thorax 10.8 IL6 TNF
3 myeloid sarcoma 10.6 EGF IL6 TNF
4 cutaneous leishmaniasis 10.6 HGF IL6 TNF
5 tinea favosa 10.6 IL6 NGF TNF
6 uterine corpus dissecting leiomyoma 10.6 EGF IL6 NGF
7 esophagus leiomyoma 10.6 IL6 MUC1 TNF
8 aortic arch interruption 10.6 IL6 TNF
9 scrotal carcinoma 10.5 FGF2 IL6 TNF
10 germ cell and embryonal cancer 10.5 IL6 LTF TNF
11 segmental odontomaxillary dysplasia 10.5 FGF2 LTF TNF
12 paranasal sinus sarcoma 10.5 HGF IL6 TNF
13 spinal stenosis 10.5 ARG1 IL6 TNF
14 trichodysplasia-amelogenesis imperfecta syndrome 10.4 FGF7 HGF
15 cytomegalovirus disease in patients with impaired cell mediated immunity deemed at risk 10.4 IL6 LCN1 TNF
16 bile duct mucoepidermoid carcinoma 10.4 MUC1 MUC5AC
17 mikulicz disease 10.4 IL6 LTF NGF TNF
18 neovascular glaucoma 10.4 EGF IL6 NGF TNF
19 lung disease 10.4 MUC1 TNF
20 optic nerve hypoplasia 10.3 FGF2 IL6 TNF
21 spirillary rat-bite fever 10.3 IL6 TNF
22 renal fibrosis 10.3 FGF2 HGF IL6 TNF
23 tibialis tendinitis 10.3 EGF FGF2 HGF TNF
24 granulomatous orchitis 10.3 IL6 MUC1 TNF
25 histiocytic and dendritic cell cancer 10.2 EGF IL6 LACRT TNF
26 premature ovarian failure 12 10.2 IL6 MUC5AC TNF
27 acute chest syndrome 10.2 IL6 MUC5AC TNF
28 toxoplasmosis 10.1 IL6 TNF
29 testicular trophoblastic tumor 10.1 MUC1 MUC5AC
30 tuberculum sellae meningioma 10.1 IL6 LTF S100A8 TNF
31 conjunctivitis 10.0
32 cataract 10.0
33 allergic conjunctivitis 10.0
34 rheumatoid arthritis 9.9
35 arthritis 9.9
36 thyroiditis 9.8
37 keratitis 9.8
38 hematopoietic stem cell transplantation 9.8
39 diamond-blackfan anemia 3 9.8 FGF2 FGF7 HGF MUC1 TNF
40 idiopathic central precocious puberty 9.8 MUC4 MUC5AC
41 mucoepidermoid esophageal carcinoma 9.7 MUC1 MUC4 MUC5AC
42 bestiality 9.7 MUC1 MUC4 MUC5AC
43 uremic neuropathy 9.7 MUC1 MUC4 MUC5AC
44 sjogren's syndrome 9.7
45 ocular melanoma 9.7
46 melanoma 9.7
47 post-traumatic stress disorder 9.7
48 systemic lupus erythematosus 9.7
49 urbach-wiethe disease 9.7
50 bullous pemphigoid 9.7

Graphical network of the top 20 diseases related to Dry Eye Syndrome:



Diseases related to Dry Eye Syndrome

Symptoms & Phenotypes for Dry Eye Syndrome

UMLS symptoms related to Dry Eye Syndrome:


dryness of eye, dacryops

MGI Mouse Phenotypes related to Dry Eye Syndrome:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 9.23 AQP5 EGF FGF2 FGF7 IL6 MUC5AC

Drugs & Therapeutics for Dry Eye Syndrome

Drugs for Dry Eye Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 325)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 22916-47-8 4189
2
Povidone Approved Phase 4 9003-39-8
3
Dipivefrin Approved Phase 4,Phase 3 52365-63-6 3105
4
Ephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 299-42-3 9294
5
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 90-82-4 7028
6
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
7
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2 564-25-0 54671203
8
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
9
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
10
Calcium Carbonate Approved Phase 4 471-34-1
11
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 9004-61-9 53477741 24759
14
Glycerol Approved, Investigational Phase 4,Phase 2,Phase 3 56-81-5 753
15
Loteprednol Approved Phase 4,Phase 3,Phase 2 82034-46-6, 129260-79-3 444025 9865442
16
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
17 Castor oil Approved, Vet_approved Phase 4
18
Ethanol Approved Phase 4,Phase 2 64-17-5 702
19
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
20
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
21
Menthol Approved Phase 4,Phase 2 2216-51-5 16666
22
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
23
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
24
Ofloxacin Approved Phase 4 82419-36-1 4583
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
26
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
27
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
28
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
29
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
30
Travoprost Approved Phase 4 157283-68-6 5282226
31
Pilocarpine Approved Phase 4 54-71-7, 92-13-7 5910
32
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
33
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
34
Sulfacetamide Approved Phase 4 144-80-9 5320
35
Tobramycin Approved, Investigational Phase 4,Phase 1 32986-56-4 5496 36294
36
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
37
Sorbitol Approved Phase 4 50-70-4 5780
38
Benzocaine Approved Phase 4 1994-09-7, 94-09-7 2337
39
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
40
Lymecycline Approved Phase 4 992-21-2 5280963
41
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
42 Tocopherol Approved, Nutraceutical Phase 4
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
44
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
45
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
46
Dehydroepiandrosterone Approved, Nutraceutical Phase 4,Phase 2 53-43-0 9860744
47
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538
48 tannic acid Approved, Nutraceutical Phase 4
49 Gallopamil Investigational Phase 4 16662-47-8
50
Bromfenac Approved July 1997 Phase 4,Phase 3,Phase 2 91714-94-2 60726

Interventional clinical trials:

(show top 50) (show all 709)

id Name Status NCT ID Phase Drugs
1 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
2 A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome Unknown status NCT00344721 Phase 4 Essential fatty acid supplement
3 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
4 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
5 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
6 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
7 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
8 Patient Satisfaction and Tear Osmolarity With the Use of Blink Tears, Blink Gel Tears and Systane Balance Unknown status NCT01589640 Phase 4
9 Lipids of the Human Tear Film and Their Effect on Tear Stability Unknown status NCT00803452 Phase 4 doxycycline;essential fatty acid;azithromycin
10 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Unknown status NCT01533480 Phase 4 Zirgan;genteal gel
11 Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue Unknown status NCT00543166 Phase 4 dehydroepiandrosterone
12 Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome Unknown status NCT02370550 Phase 4 Cyclosporin A;Prednisone;Placebo;Calcium carbonate D
13 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
14 Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome Completed NCT01864330 Phase 4
15 Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz Completed NCT01742884 Phase 4
16 Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy Completed NCT00349440 Phase 4 Cyclosporine, Refresh Plus
17 Comparative Study of 0.5% Carboxymethylcellulose With 0.005% Stabilized Oxychlorocomplex (PURITE™) Versus 0.5% Carboxymethylcellulose in the Treatment of Dry Eye Completed NCT00386646 Phase 4 0.5% carboxymethylcellulose (CMC) with purite and CMC alone
18 Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome Completed NCT02585453 Phase 4
19 A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome Completed NCT02139033 Phase 4 Retaine™
20 TearLab Refractive Surgery Dry Eye Study Completed NCT01176045 Phase 4
21 A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN) Completed NCT02014922 Phase 4 TheraTears® Lubricant Eye Drop;TheraTears® preservative-free single-use containers
22 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear vs. Systane for Dry Eye Signs, Symptoms & Refractive Regression Associated With Myopic Laser in Situ Keratomilieusis (LASIK). Completed NCT00620893 Phase 4 PEG- 400 based artificial tear;Systane
23 Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye Completed NCT03183089 Phase 4 Rohto Dry-Aid®;Systane® Ultra
24 Kynex Versus Refresh Plus Study in Subject With Dry Eye Completed NCT00809198 Phase 4
25 The Utility of in Vivo Confocal Microscopy to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease Completed NCT02120079 Phase 4 Lotemax;Artificial Tears
26 Efficacy of Optive Versus Systane Concomitant With Restasis (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00399061 Phase 4 Systane, Optive, Restasis
27 The Effect of Ocular Lubricant Eyedrops on Lid Parallel Conjunctival Folds and Other Signs and Symptoms of Dry Eye Completed NCT01268735 Phase 4 Lubricating eyedrops containing hydroxypropyl-guar
28 Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease Completed NCT00567177 Phase 4 Restasis, Refresh Plus
29 Comparison of Autologous Serum Versus Preservative Free Artificial Tear Completed NCT02752763 Phase 4 %40 diluted Autologous serum;Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)
30 Safety and Efficacy of Carboxymethylcellulose for Ocular Surface Integrity in Symptomatic Dry Eye Completed NCT00987727 Phase 4 carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD);sodium hyaluronate 0.18% (VISMED® Multi)
31 A Prospective, Randomized, Double-Masked, Single Center, Clinical Comparison of the Use of Systane Ultra in the Management of Dry Eyes in Bilateral Eyes Completed NCT00781092 Phase 4
32 Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops Completed NCT01850979 Phase 4 Tacrolimus;Olive Oil
33 Evaluate Artificial Tear Efficacy in Moderate to Severe Dry Eye Completed NCT00724412 Phase 4
34 Comparison of Systane Free vs. Saline in the Treatment of Dry Eye Completed NCT00388791 Phase 4 Systane Free
35 Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Completed NCT00469573 Phase 4 1. Optive
36 A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye Completed NCT02951910 Phase 4
37 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
38 Efficacy and Safety of a New Multi-dose Lubricant Eye Drop Concomitant With Restasis® (Cyclosporine A) for the Treatment of Dry Eye Symptoms Completed NCT00405457 Phase 4 Restasis, Optive Tears
39 A Clinical Evaluation Pilot Study of the Efficacy of Blink® Tears Lubricant Eye Drops for the Relief of Dry Eye Symptoms Following Implantation of Tecnis® Multifocal Introcular Lens Completed NCT01061268 Phase 4 No topical artificial tear;Blink® Tears Lubricant Eye Drops
40 Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis Completed NCT00407043 Phase 4 Lotemax;Restasis
41 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
42 Efficacy Study of a New Eyedrop on Silicone Hydrogel Contact Lens Wearers With Dry Eye Complaints Completed NCT01543061 Phase 4
43 Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra) Completed NCT02985827 Phase 4 Rohto (r) Hydra;Systane (r) Ultra
44 Performance and Acceptance of Optive Versus Hylocomod Eyedrops in Patients With Dry Eye Symptoms Completed NCT00761202 Phase 4 A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®;Sodium hyaluronate
45 Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality Completed NCT00622037 Phase 4 PEG-400 based artificial tear;Systane
46 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms Completed NCT00938704 Phase 4 carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
47 Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease Completed NCT02004067 Phase 4 Restasis;Refresh Endura
48 Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients Completed NCT01682460 Phase 4 Refresh Tears Lubricant Eye Drops (Allergan)
49 Efficacy of Systane Ultra in Post Menopausal Women With Dry Eye Completed NCT01105910 Phase 4
50 A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye Completed NCT02117687 Phase 4 carboxymethylcellulose 0.5%/glycerin 0.9%;sodium hyaluronate 0.18%

Search NIH Clinical Center for Dry Eye Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: dry eye syndromes

Genetic Tests for Dry Eye Syndrome

Anatomical Context for Dry Eye Syndrome

MalaCards organs/tissues related to Dry Eye Syndrome:

39
Eye, Salivary Gland, Thyroid, Testes, B Cells, Bone, Skin

Publications for Dry Eye Syndrome

Articles related to Dry Eye Syndrome:

(show top 50) (show all 267)
id Title Authors Year
1
Automated Measurement of Tear Film Dynamics and Lipid Layer Thickness for Assessment of Non-SjAPgren Dry Eye Syndrome With Meibomian Gland Dysfunction. ( 28060064 )
2017
2
Topical administration of Esculetin as a potential therapy for experimental dry eye syndrome. ( 28643798 )
2017
3
Lower Serum Vitamin D Level Was Associated with Risk of Dry Eye Syndrome. ( 28487505 )
2017
4
Aqueous Deficient Dry Eye Syndrome Post Orbital Radiotherapy: A 10-Year Retrospective Study. ( 28660094 )
2017
5
Sodium Hyaluronate in the Treatment of Dry Eye Syndrome: A Systematic Review and Meta-Analysis. ( 28827614 )
2017
6
Dry Eye Syndrome in Menopause and Perimenopausal Age Group. ( 28706404 )
2017
7
Tear Fluid Protein Changes in Dry Eye Syndrome Associated with Rheumatoid Arthritis: A Proteomic Approach. ( 27789276 )
2017
8
Punctal occlusion for dry eye syndrome. ( 28649802 )
2017
9
A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome. ( 28441068 )
2017
10
Evaluation of Clinical Efficacy and Safety of a Novel Cyclosporin A Nanoemulsion in the Treatment of Dry Eye Syndrome. ( 28759302 )
2017
11
Risk of dry eye syndrome in patients treated with whole-brain radiotherapy. ( 28784430 )
2017
12
Epigallocatechin Gallate-Loaded Gelatin-g-Poly(N-Isopropylacrylamide) as a New Ophthalmic Pharmaceutical Formulation for Topical Use in the Treatment of Dry Eye Syndrome. ( 28839279 )
2017
13
Effects of adjuvant omega-3 fatty acid supplementation on dry eye syndrome following cataract surgery: A randomized clinical trial. ( 28367524 )
2017
14
Dry Eye Syndrome After Proton Therapy of Ocular Melanomas. ( 28586953 )
2017
15
Protective effects of carbenoxolone, an 11I^-HSD1 inhibitor, against chemical induced dry eye syndrome. ( 28887719 )
2017
16
Aging eye microbiota in Dry Eye Syndrome in patients treated with Enterococcus faecium and Saccharomyces boulardii. ( 28676009 )
2017
17
Efficacy of nutritional supplementation with omega-3 and omega-6 fatty acids in dry eye syndrome: a systematic review of randomized clinical trials. ( 28371493 )
2017
18
Fingerprick autologous blood: a novel treatment for dry eye syndrome. ( 28622325 )
2017
19
Magnitude of diabetes and hypertension among patients with Dry Eye Syndrome at a tertiary hospital of Riyadh, Saudi Arabia - A case series. ( 28559720 )
2017
20
Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study. ( 28752695 )
2017
21
Herbal Supplement in a Buffer for Dry Eye Syndrome Treatment. ( 28771187 )
2017
22
The Use of Topical Corticosteroids for Treatment of Dry Eye Syndrome. ( 28910552 )
2017
23
An eye on nutrition: The role of vitamins, essential fatty acids, and antioxidants in age-related macular degeneration, dry eye syndrome, and cataract. ( 26903189 )
2016
24
A Divalent PAMAM-Based Matrix Metalloproteinase/Carbonic Anhydrase Inhibitor for the Treatment of Dry Eye Syndrome. ( 26692423 )
2016
25
Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: A cross-sectional analysis. ( 27428227 )
2016
26
Synergistic Effect of Artificial Tears Containing Epigallocatechin Gallate and Hyaluronic Acid for the Treatment of Rabbits with Dry Eye Syndrome. ( 27336157 )
2016
27
Angiogenin for the Diagnosis and Grading of Dry Eye Syndrome. ( 27247515 )
2016
28
Efficacy of a New Ocular Surface Modulator in Restoring Epithelial Changes in an In Vitro Model of Dry Eye Syndrome. ( 27163340 )
2016
29
Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome. ( 26873225 )
2016
30
Dry Eye Syndrome Risks in Patients With Fibromyalgia: A National Retrospective Cohort Study. ( 26825913 )
2016
31
Effect of human milk as a treatment for dry eye syndrome in a mouse model. ( 27667918 )
2016
32
Size of the Lesions of Superficial Punctate Keratitis in Dry Eye Syndrome Observed With a Slit Lamp. ( 27124778 )
2016
33
Prevalence of dry eye syndrome in residents of surgical specialties. ( 27422541 )
2016
34
Low Serum 25-Hydroxyvitamin D Levels Are Associated with Dry Eye Syndrome. ( 26807908 )
2016
35
Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome. ( 27100624 )
2016
36
Cryopreservation and hypothermic storage of lacrimal gland: towards enabling delivery of regenerative medicine therapies for treatment of dry eye syndrome. ( 27976538 )
2016
37
Efficacy of Several Therapeutic Agents in a Murine Model of Dry Eye Syndrome. ( 27053565 )
2016
38
Alcohol consumption and dry eye syndrome: a Meta-analysis. ( 27803869 )
2016
39
Dry Eye Syndrome in Patients with Diabetes Mellitus: Prevalence, Etiology, and Clinical Characteristics. ( 27213053 )
2016
40
Serum 25-Hydroxyvitamin D Levels and Dry Eye Syndrome: Differential Effects of Vitamin D on Ocular Diseases. ( 26894581 )
2016
41
A randomized, double-blind, placebo-controlled study of oral antioxidant supplement therapy in patients with dry eye syndrome. ( 27274185 )
2016
42
Over the counter (OTC) artificial tear drops for dry eye syndrome. ( 26905373 )
2016
43
Automated Measurement of Tear Film Dynamics and Lipid Layer Thickness for Assessment of Non-SjAPgren Dry Eye Syndrome With Meibomian Gland Dysfunction. ( 27941381 )
2016
44
Metabolic syndrome risk factors and dry eye syndrome: a Meta-analysis. ( 27500114 )
2016
45
A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. ( 27445067 )
2016
46
The Association between Symptoms of Dry Eye Syndrome and Metabolic Outcome in a General Population in Korea. ( 27366012 )
2016
47
A Comprehensive Review of Sex Disparities in Symptoms, Pathophysiology, and Epidemiology of Dry Eye Syndrome. ( 27101252 )
2016
48
Examining the relationship between hormone therapy and dry-eye syndrome in postmenopausal women: a cross-sectional comparison study. ( 27003590 )
2016
49
Correlation of vitamin D levels with tear film stability and secretion in patients with dry eye syndrome. ( 27874256 )
2016
50
Analysis of Factors Associated With the Tear Film Lipid Layer Thickness in Normal Eyes and Patients With Dry Eye Syndrome. ( 27537256 )
2016

Variations for Dry Eye Syndrome

Expression for Dry Eye Syndrome

Search GEO for disease gene expression data for Dry Eye Syndrome.

Pathways for Dry Eye Syndrome

Pathways related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 24)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 ARG1 EGF FGF2 FGF7 HGF IL6
2
Show member pathways
13.31 EGF FGF2 FGF7 HGF IL6 NGF
3
Show member pathways
13.25 EGF FGF2 FGF7 HGF IL6 MUC1
4
Show member pathways
13.17 EGF FGF2 FGF7 HGF IL6 NGF
5
Show member pathways
13.11 AQP5 EGF FGF2 FGF7 HGF IL6
6
Show member pathways
12.95 EGF FGF2 FGF7 HGF IL6 NGF
7
Show member pathways
12.92 EGF FGF2 FGF7 HGF IL6 NGF
8
Show member pathways
12.59 EGF FGF2 FGF7 HGF NGF
9 12.56 EGF FGF2 FGF7 NGF TNF
10 12.52 EGF FGF2 FGF7 HGF IL6
11 12.48 EGF FGF2 FGF7 HGF IL6 NGF
12
Show member pathways
12.21 IL6 MUC5AC S100A8 TNF
13
Show member pathways
12.12 EGF FGF2 FGF7 HGF IL6 NGF
14 11.78 EGF FGF2 FGF7 HGF IL6
15 11.77 ARG1 IL6 TNF
16 11.76 EGF FGF2 IL6
17 11.67 EGF FGF2 NGF
18 11.61 FGF2 HGF IL6 MUC1 TNF
19 11.54 EGF FGF2 FGF7 HGF IL6 NGF
20 11.39 FGF7 IL6 TNF
21 11.36 HGF IL6 TNF
22 11.3 EGF FGF2 HGF IL6
23 11.26 AQP5 EGF HGF
24 10.9 EGF FGF2 FGF7 HGF IL6 TNF

GO Terms for Dry Eye Syndrome

Cellular components related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 ARG1 EGF FGF2 HGF IL6 LACRT
2 extracellular region GO:0005576 9.55 ARG1 EGF FGF2 FGF7 HGF IL6
3 platelet alpha granule lumen GO:0031093 9.54 EGF HGF ORM1
4 Golgi lumen GO:0005796 9.46 MUC1 MUC4 MUC5AC NGF
5 specific granule lumen GO:0035580 9.43 ARG1 LTF ORM1
6 extracellular exosome GO:0070062 10.02 AQP5 ARG1 EGF LCN1 LTF MUC1

Biological processes related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.91 EGF FGF2 FGF7 HGF IL6 LACRT
2 defense response to bacterium GO:0042742 9.9 LACRT LTF S100A8 TNF
3 wound healing GO:0042060 9.83 FGF2 IL6 S100A8
4 peptidyl-tyrosine phosphorylation GO:0018108 9.83 EGF FGF2 FGF7 HGF
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.8 NGF S100A8 TNF
6 MAPK cascade GO:0000165 9.8 EGF FGF2 FGF7 HGF TNF
7 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.79 HGF IL6 NGF
8 response to wounding GO:0009611 9.79 ARG1 FGF7 IL6
9 positive regulation of epithelial cell proliferation GO:0050679 9.77 FGF7 IL6 LACRT
10 O-glycan processing GO:0016266 9.76 MUC1 MUC4 MUC5AC
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.76 IL6 LTF S100A8 TNF
12 positive regulation of MAP kinase activity GO:0043406 9.75 EGF FGF2 TNF
13 positive regulation of osteoblast differentiation GO:0045669 9.74 HGF IL6 LTF
14 humoral immune response GO:0006959 9.73 IL6 LTF TNF
15 retina homeostasis GO:0001895 9.67 LCN1 LTF PRR4
16 activation of MAPK activity GO:0000187 9.67 EGF FGF2 HGF TNF
17 cellular response to hepatocyte growth factor stimulus GO:0035729 9.65 HGF IL6
18 positive chemotaxis GO:0050918 9.65 FGF2 FGF7 HGF
19 acute inflammatory response GO:0002526 9.64 IL6 S100A8
20 branching involved in salivary gland morphogenesis GO:0060445 9.63 FGF7 IL6
21 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 9.62 LACRT LTF
22 negative regulation of lipid storage GO:0010888 9.61 IL6 TNF
23 phosphatidylinositol phosphorylation GO:0046854 9.56 EGF FGF2 FGF7 HGF
24 positive regulation of NFAT protein import into nucleus GO:0051533 9.55 LACRT TNF
25 epithelial cell proliferation involved in salivary gland morphogenesis GO:0060664 9.54 IL6 TNF
26 regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling GO:0060665 9.51 FGF7 HGF
27 negative regulation of interleukin-6 production GO:0032715 9.5 HGF ORM1 TNF
28 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.46 EGF FGF2 FGF7 HGF
29 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.35 EGF FGF7 HGF IL6 LACRT
30 phosphatidylinositol-mediated signaling GO:0048015 9.1 EGF FGF2 FGF7 HGF MUC5AC NGF
31 negative regulation of apoptotic process GO:0043066 10.04 HGF IL6 LACRT LTF NGF

Molecular functions related to Dry Eye Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein tyrosine kinase activity GO:0004713 9.62 EGF FGF2 FGF7 HGF
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.56 EGF FGF2 FGF7 HGF
3 chemoattractant activity GO:0042056 9.33 FGF2 FGF7 HGF
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGF FGF2 FGF7 HGF
5 growth factor activity GO:0008083 9.17 EGF FGF2 FGF7 HGF IL6 LACRT

Sources for Dry Eye Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....